Brain metastasis in renal cell cancer responding to sunitinib

Anticancer Research

Volumn 27, Issue 6 C, 2007, Pages 4255-4257

  Koutras, Angelos K ^a   Krikelis, Dimitrios ^a   Alexandrou, Natassa ^a   Starakis, Ioannis ^a   Kalofonos, Haralabos P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Brain metastases; Renal cell cancer; Sunitinib

Indexed keywords

ALPHA INTERFERON; METHYLPREDNISOLONE; OLMESARTAN; SUNITINIB;

ADULT; ANAMNESIS; ANEMIA; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN METASTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; PYRROLES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 37549027153     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Chow LQ and Eckhardt SG: Sunitinib: From rational design to clinical efficacy. J Clin Oncol 25: 884-896, 2007.
2. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM and Michaelson MD: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524, 2006.
3. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ and Rini BI: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24, 2006.
4. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.
5. Gay PC, Litchy WJ and Cascino TL: Brain metastasis in hypernephroma. J Neurooncol 5: 51-56, 1987.
6. Villano JL, Mauer AM and Vokes EE: A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann Oncol 14: 656-658, 2003.
7. Ceresoli GL, Cappuzzo F, Gregore V, Bartolini S, Crinò L and Villa E: Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15: 1042-1047, 2004.
8. Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, Okada T, Hisamoto A and Tanimoto M: Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46: 255-261, 2004.
9. Lai CS, Boshoff C, Falzon M and Lee SM: Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 61: 91, 2006.
10. Popat S, Hughes S, Papadopoulos P, Wilkins A, Moore S, Priest K, Meehan L, Norton A and O'Brien M: Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer 56: 135-137, 2007.
11. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S and Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743, 2006.